Arcutis Biotherapeutics (ARQT) closed at $32.82 on October 20, 2026, up 2.9% from the previous close, on volume of 3,809,885 shares (30-day average 3,129,140).
Data as of October 20, 2026.
20-Oct-2026
Globe Newswire (Fri, 9-Oct 8:00 AM ET)
Arcutis' ZORYVE (roflumilast) Wins 2026 Marie Claire Beauty Award
Globe Newswire (Tue, 6-Oct 8:19 AM ET)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 2-Oct 4:00 PM ET)
Globe Newswire (Tue, 29-Sep 9:15 AM ET)
PRNewswire (Fri, 4-Sep 7:16 PM ET)
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Globe Newswire (Wed, 2-Sep 4:00 PM ET)
PRNewswire (Thu, 20-Aug 1:25 PM ET)
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 5-Aug 4:00 PM ET)
Arcutis Highlights Robust Dermatology Pipeline Ahead of Major Investor Conferences
Market Chameleon (Tue, 28-Oct 6:29 AM ET)
Market Chameleon (Tue, 28-Oct 5:06 AM ET)
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.
Arcutis Biotherapeutics trades on the NASDAQ stock market under the symbol ARQT.
As of October 20, 2026, ARQT stock price climbed to $32.82 with 3,809,885 million shares trading.
ARQT has a beta of 0.41, meaning it tends to be less sensitive to market movements. ARQT has a correlation of 0.01 to the broad based SPY ETF.
ARQT has a market cap of $4.13 billion. This is considered a Mid Cap stock.
Last quarter Arcutis Biotherapeutics reported $130 million in Revenue and $.11 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.06.
In the last 3 years, ARQT traded as high as $33.30 and as low as $1.76.
The top ETF exchange traded funds that ARQT belongs to (by Net Assets): IJR, XBI, IWM, VTI, IJT.
ARQT has outperformed the market in the last year with a price return of +57.2% while the SPY ETF gained +15.7%. ARQT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.2% and +37.2%, respectively, while the SPY returned +3.9% and -1.3%, respectively.
ARQT support price is $30.65 and resistance is $33.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARQT shares will trade within this expected range on the day.
